AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 279: H2829-H2837, 2000;
0363-6135/00 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Douillet, C. D.
Right arrow Articles by Jaffa, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Douillet, C. D.
Right arrow Articles by Jaffa, A. A.
Vol. 279, Issue 6, H2829-H2837, December 2000

Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-beta and MAPK

Christelle D. Douillet1, Victoria Velarde1, Julie T. Christopher1, Ronald K. Mayfield1,3, Maria E. Trojanowska1, and Ayad A. Jaffa1,2

Departments of 1 Medicine and 2 Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, and 3 Ralph H. Johnson Veteran Affairs Medical Center, Charleston, South Carolina 29425


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Accumulation of extracellular matrix (ECM) is a hallmark feature of vascular disease. We have previously shown that hyperglycemia induces the expression of B2-kinin receptors in vascular smooth muscle cells (VSMC) and that bradykinin (BK) and hyperglycemia synergize to stimulate ECM production. The present study examined the cellular mechanisms through which BK contributes to VSMC fibrosis. VSMC treated with BK (10-8 M) for 24 h significantly increased alpha 2(I) collagen mRNA levels. In addition, BK produced a two- to threefold increase in alpha 2(I) collagen promoter activity in VSMC transfected with a plasmid containing the alpha 2(I) collagen promoter. Furthermore, treatment of VSMC with BK for 24 h produced a two- to threefold increase in the secretion rate of tissue inhibitor of metalloproteinase 1 (TIMP-1). The increase in alpha 2(I) collagen mRNA levels and alpha 2(I) collagen promoter activity, as well as TIMP-1 secretion, in response to BK were blocked by anti-transforming growth factor-beta (anti-TGF-beta ) neutralizing antibodies. BK (10-8 M) increased the endogenous production of TGF-beta 1 mRNA and protein levels. Inhibition of the mitogen-activated protein kinase (MAPK) pathway by PD-98059 inhibited the increase of alpha 2(I) collagen promoter activity, TIMP-1 production, and TGF-beta 1 protein levels observed in response to BK. These findings provide the first evidence that BK induces collagen type I and TIMP-1 production via autocrine activation of TGF-beta 1 and implicate MAPK pathway as a key player in VSMC fibrosis in response of BK.

collagen; tissue inhibitor of metalloproteinase 1; transforming growth factor-beta ; mitogen-activated protein kinase


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

VASCULAR SMOOTH MUSCLE CELL (VSMC) expansion and the resultant increased extracellular matrix (ECM) deposition play pivotal roles in the progression of atherogenesis (2). Increases in ECM components such as collagens types I and IV are found in plaque areas of aortas from type 1 diabetic patients (32). These changes in matrix composition may impair vascular function by changing VSMC from their contractile state to a synthetic state (5). Although the precise mechanisms underlying these changes are undefined, the interaction between arterial smooth muscle cells and the surrounding matrix suggests a dynamic system in which changes in composition and spatial organization of matrix itself may profoundly change the metabolic and proliferative activity of VSMC (34, 42). Collagen formation is the major contributor to the growth of atherosclerotic lesions (2). Of the various types of collagens, type I is the primary component of atherosclerotic plaque and is synthesized by arterial smooth muscle cells in response to growth factors (2). Thus matrix deposition is a characteristic part of the sclerotic process that contributes to vascular function impairment by disrupting normal cell-cell interaction and modifying tissue elasticity.

Among the factors that play a central role in vascular fibrosis is transforming growth factor-beta (TGF-beta ). TGF-beta has been shown to stimulate collagen expression in VSMC and also to influence the expression of some matrix metalloproteinases (MMP) and their tissue inhibitors (TIMPs). Since matrix deposition is the result of a balance between synthesis and degradation of ECM components, it is conceivable that the delicate balance between MMP and TIMP, as well as the rate of ECM synthesis, determine the final matrix accumulation.

The localization of components of the kallikrein-kinin system within the vascular wall suggests this system has a role in the regulation of vascular tone, hypertension, and atherogenesis (22, 24). Kallikrein and its mRNA are expressed in isolated arteries and veins and in cultured VSMC (29, 33). Kininogen, the substrate for kinin generation by kallikrein, kininase activity, and B2-kinin receptors are present in VSMC (30). Thus locally generated kinins can act in an autocrine or paracrine fashion to influence vascular function. The physiological actions of bradykinin (BK) are mediated via generation of second messengers such as nitric oxide and eicosanoids (17, 36). BK relaxes VSMC through synthesis and release of nitric oxide from the endothelium, but in states of vascular injury in which endothelial integrity is compromised, BK can act directly on VSMC, to increase intracellular calcium and cause contraction (4).

The signaling pathways leading to VSMC fibrosis are just beginning to be studied and seem to be derived from multiple sources. Our recent data demonstrate that BK stimulates early mitogenic signals in VSMC. Through activation of its B2 receptors, BK stimulates activation and nuclear translocation of p42mapk and p44mapk and induces expression of c-fos and c-jun mRNA levels and formation of the AP-1 complex (11, 44). The cellular signals through which BK stimulates p42mapk and p44mapk activation and c-fos mRNA expression in VSMC involves activation of a calcium/calmodulin pathway, src kinase, protein kinase C, and generation of reactive oxygen species (14, 28, 44).

Therefore, the present studies were designed to explore the role of BK in mediating VSMC fibrosis. We found that BK induces alpha 2 chain of type I [alpha 2(I)] collagen mRNA levels, alpha 2(I) collagen promoter activity, and TIMP-1 production via autocrine activation of TGF-beta 1. In addition, our findings demonstrate that BK signals via the mitogen-activated protein kinase (MAPK) pathway to mediate its effects on alpha 2(I) collagen and TIMP-1 production. These findings provide the first evidence for a potential role for BK in VSMC fibrosis.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Cell culture. Rat aortic VSMC from male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) were prepared by a modification of the method of Majack and Clowes (21). A 2-cm segment of thoracic aorta cleaned of fat and adventitia was incubated in 1 mg/ml collagenase for 3 h at room temperature. The aorta was then cut into small sections and placed into a culture flask for explantation in minimal essential media (MEM) containing 10% FBS, 1% nonessential amino acids, 100 mU/ml penicillin, and 100 µg/ml streptomycin (Cellgro; Mediatech, Herndon, VA). Cells were incubated at 37°C in a humidified atmosphere of 95% air-5% CO2. Medium was changed every 3-4 days, and cells were passaged every 6-8 days by harvesting with trypsin-EDTA. Cell viability was assessed by standard dye exclusion techniques using 1% trypan blue. VSMC were identified by the following criteria. They stained positive for intracellular cytoskeletal fibrils of alpha -actin and smooth muscle cell-specific myosin (indicative of contractile cell) and negative for factor VIII antigens. VSMC isolated by this procedure were homogenous and were used in all studies between passages 2 and 6.

RNA extraction and Northern blotting. VSMC in 15-cm dishes were rendered quiescent by growing them in serum-free media for 48 h. Cells were then stimulated with agonists as indicated. Total RNA from the cells was extracted by the chloroform-phenol method (6). RNA concentration and purity were determined spectrophotometrically (Ultrospec III, Pharmacia) by absorbance at 260 and 280 nm. Total RNA (20 µg) was denatured at 65°C for 15 min and ran on 1.5% agarose gel in denaturing conditions. The gel was stained with ethidium bromide to determine the position of the 28S and 18S ribosomal RNA and to demonstrate that similar amounts of intact RNA were used for each sample. Total RNA was transferred from the gel to Nytran membrane filters (Schleicher and Schuell, Keene, NH) by a pressure transducer (PosiBlot; Stratagene, La Jolla, CA), prehybridized for 2 h, and hybridized at 55°C for 18-24 h with nick-translated cDNA probes labeled with 32P using a nick-translation kit (Bethesda Research Laboratories, Bethesda, MD). The hybridized membranes were washed and exposed to film. Autoradiographs (Kodak XAR-5 film, Eastman Kodak, Rochester, NY) of the membranes were obtained and scanned, and the intensities of the bands were quantified by NIH image 1.61/68k.

TGF-beta 1 protein level determination. VSMC were cultured in six-well plates (9.6 cm2/well). At 70% confluence, cells were serum starved by the changing of the serum-free media four times within 24 h. Cells were then stimulated for 48 h with 10-8 M BK, in presence or absence of 40 µM of PD-98059, in exactly 1.5 ml. TGF-beta 1 protein levels were determined by colorimetric enzyme-linked immunosorbent assay kit (ELISA; R&D Systems, Minneapolis, MN) in the conditioned media that were activated by HCl (to measure both active and latent TGF-beta 1) according to the manufacturer instructions, and expressed as picograms per milliliter.

Transfection of VSMC with the alpha 2(I) collagen promoter. VSMC were transfected by the calcium chloride method with a plasmid containing the alpha 2(I) collagen promoter attached to the chloramphenicol acetyl transferase (CAT) gene (-353 COL1A2 CAT); the plasmid was obtained from Promega (Madison, WI), prepared as described by Tamaki et al. (41), purified by double cesium chloride purification, and stored at 4°C. The plasmid (20 µg of plasmid DNA) in a 2 M CaCl2 solution was mixed with an equal volume of 2× DNA precipitation buffer (3 Prime right-arrow5 Prime Inc., Boulder, CO) and incubated for 30 min before addition to the cells. After 16 h of incubation, the culture medium was changed to 1% FBS in MEM. Two hours later, the cells were stimulated for 24 h as indicated. The cells were then washed in PBS and resuspended in 0.25 M Tris, pH 8.0. The CAT was extracted from the cells by four cycles of freezing-thawing and centrifugation at 13,800 g for 15 min. Protein concentrations were determined in each cell extract by Bio-Rad protein assay (Bio-Rad, Hercules, CA), and 10-20 µg of proteins from each dish were used for CAT activity assay. CAT activity of each sample was performed in presence of 2.5 mg/ml of butyryl-CoA and [14C]chloramphenicol incubated for 90 min at 37°C. Acetylated chloramphenicol was extracted by tetramethylpentadecane/xylene (2:1), and radioactivity was measured in a BetaMax counter (ICN, Costa Mesa, CA). In some experiments, 5 µg of the pSV-beta -galactosidase control vector (Promega) was cotransfected to normalize for transfection efficiency. beta -Galactosidase activity assays were measured according to the manufacturer instructions

Western blotting of TIMP-1. VSMC in 60-mm dishes were rendered quiescent by growing them in serum-free media for 24 h. Cells were then stimulated as indicated. The conditioned media were collected after 24 h and concentrated by lyophilization. Proteins were determined by Bio-Rad protein assay and resolved on SDS-PAGE. The separated proteins in the gel were transferred to Immobilon-P membrane (Millipore, Bedford, MA) and immunoblotted with goat polyclonal anti-rat TIMP-1 specific antibody (1:2,000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA). The blots were revealed by anti-goat IgG antibody conjugated with alkaline phosphatase (1:6,000 dilution, Santa Cruz Biotechnology) and CDP-Star chemiluminescent system (NEN Life Sciences Products, Boston, MA). The membranes were exposed to film (X-Omat LS, Kodak). Films were scanned, and the intensities of the bands were quantified by NIH image 1.61/68k.

Phospho-MAPK immunoblots. To measure MAPK activity, 20-25 µg of soluble protein obtained from cell lysates were subjected to SDS-PAGE. The separated proteins in the gel were transferred to polyvinylidene difluoride membranes, and immunoblotted with rabbit polyclonal phospho-specific MAPK antibodies that specifically recognize tyrosine phosphorylated p42mapk and p44mapk (New England Biolabs, Beverly, MA). The phospho-MAPK antibody was used at 1:6,000 dilution, whereas the control antibody, which recognizes total MAPK, was used at 1:4,000 dilution. The membranes were incubated overnight with the antibody buffer (TBS, 0.05% Tween 20, 1% BSA), washed in TBS-0.05% Tween 20, and exposed to goat anti-rabbit horseradish peroxidase-conjugated IgG (1:5,000) in antibody buffer for 1 h. Immunoreactive bands were visualized by a chemiluminescent method (Renaissance, New England Biolabs) using Kodak X-LS film.

Statistical analysis. Data are expressed as means ± SE and were analyzed by ANOVA and by using student's t-test for unpaired analysis. Differences were considered significant if P < 0.05.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Induction of alpha 2(I) collagen expression by BK. To investigate whether BK induces ECM formation, we measured alpha 2(I) collagen mRNA expression in VSMC treated with BK (10-8 M) for 24 h. As shown in Fig. 1A, BK produced a significant increase in alpha 2(I) collagen mRNA levels, expressed relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. The alpha 2(I) collagen mRNA levels were increased to 160% of control VSMC (BK vs. control, P < 0.003, n = 3).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   Bradykinin (BK) stimulates the expression of alpha 2(I) collagen in vascular smooth muscle cells (VSMC). A: quiescent VSMC were stimulated with BK (10-8 M) for 24 h. RNA was extracted from cells, and alpha 2(I) collagen and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels were measured by Northern blot analysis. The bar graph represents the relative intensities of alpha 2(I) collagen to GAPDH mRNA levels. Blot is representative of 3 separate experiments. B: VSMC were transfected with a plasmid containing alpha 2(I) collagen promoter and chloramphenicol acetyl transferase (CAT) gene as a reporter for the activity of the alpha 2(I) collagen. Transfected cells were stimulated for 24 h with BK (10-8 M) or transforming growth factor-beta 1 (TGF-beta 1, 1 ng/ml) as a positive control. Bar graph represents the alpha 2(I) collagen promoter CAT activity expressed as a percentage of control. Results are representative of 8 separate experiments. *P < 0.005 vs. control.

We next assessed whether BK can induce transcriptional activation of alpha 2(I) collagen gene by measuring its effect on the activity of alpha 2(I) collagen promoter. VSMC transfected with a plasmid containing the alpha 2(I) collagen promoter were stimulated for 24 h with either BK (10-8 M) or TGF-beta 1 (1 ng/ml) as positive control. The CAT activity (used as a reporter for the activity of the collagen promoter) was determined in the cell lysate.

The results (Fig. 1B) demonstrate for the first time that BK can directly increase the activity of the collagen promoter. BK produced a 2.5-fold increase in alpha 2(I) collagen promoter activity, whereas TGF-beta 1 produced a fourfold increase (control vs. BK or TGF-beta 1, P < 0.005, n = 8 experiments).

Induction of TGF-beta 1 expression by BK. To define the cellular mechanisms through which BK increased collagen expression, the ability of BK to stimulate the endogenous production of TGF-beta was examined. We measured the TGF-beta 1 mRNA levels in VSMC treated with BK (10-8 M) for various times. BK treatment resulted in a significant increase in TGF-beta 1 mRNA levels/GAPDH mRNA levels above control. This increase in TGF-beta 1 was observed as early as 4 h, maintained at 6 h, and returned to normal values by 24 h (P < 0.02, BK vs. 0 h, n = 4 experiments, Fig. 2).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   Induction of TGF-beta mRNA levels by BK in VSMC. Quiescent VSMC were stimulated with BK (10-8 M) for various times (0, 4, 6, 8, and 24 h). RNA was extracted from cells, and TGF-beta 1 and GAPDH mRNA levels were measured by Northern blot analysis. Top: relative intensities of TGF-beta 1 to GAPDH mRNA levels. Bottom: blot representative of 4 separate experiments. *P < 0.02 vs. 0 h (control).

Role of TGF-beta in BK-induced alpha 2(I) collagen expression. To further define the role of TGF-beta in BK signaling, we examined whether the increase in alpha 2(I) collagen mRNA levels or promoter activity in response to BK are mediated via autocrine activation of TGF-beta . VSMC were treated with BK (10-8 M) for 24 h in the presence and absence of neutralizing anti-TGF-beta antibodies (20 µg/ml, R&D Systems). This concentration of anti-TGF-beta antibody has been shown to neutralize the effects of TGF-beta on mesangial cell proliferation and matrix formation (39, 45). The results shown in Fig. 3A indicate that the ability of BK to induce alpha 2(I) collagen mRNA levels is blocked by the anti-TGF-beta neutralizing antibody (P < 0.05, BK vs. BK+TGF-beta neutralizing antibody, n = 3). We also examined the effects of TGF-beta neutralizing antibody on VSMC transfected with the alpha 2(I) collagen promoter and stimulated with BK (10-8 M) for 24 h. Although we have observed differences in the magnitude of response to BK between different cell lines, once again, BK produced a significant increase in CAT activity compared with unstimulated control cells (BK vs. control, P < 0.01, n = 5, Fig. 3B). This increase in CAT activity in response to BK stimulation was completely blocked in the presence of anti-TGF-beta neutralizing antibody. Anti-TGF-beta neutralizing antibody had no significant effect on basal CAT activity (Fig. 3B).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   BK induces alpha 2(I) collagen expression via autocrine activation of TGF-beta . A: quiescent VSMC were stimulated for 24 h with 10-8 M BK in presence or absence of 20 µg/ml of neutralizing anti-TGF-beta antibody (TGF-beta NA). RNA was extracted from cells and alpha 2(I) collagen and GAPDH mRNA levels were measured by Northern blot analysis. Values represent relative intensities of alpha 2(I) collagen mRNA to GAPDH mRNA levels. B: VSMC were transfected with a plasmid containing alpha 2(I) collagen promoter and CAT gene as a reporter for the activity of the alpha 2(I) collagen. Transfected cells were stimulated for 24 h with 10-8 M BK in presence or absence of 20 µg/ml of neutralizing anti-TGF-beta antibody (TGF-beta NA). Bar graph represents the alpha 2(I) collagen promoter CAT activity expressed as percentage of control and is representative of 5 separate experiments. *P < 0.01 vs. control. dagger P < 0.05 vs. BK.

BK increases TIMP-1 secretion via a TGF-beta -dependent mechanism. TIMPs are proteins that regulate the activity of MMPs and play an integral part in the turnover rate of ECM under physiological and pathological conditions (13). Thus it is conceivable that VSMC matrix accumulation is the net result of signals that promote increased TIMP activity. To address this possibility, we examined the effects of BK on the secretion rate of TIMP-1 in VSMC and explored the role of TGF-beta in mediating the effects of BK on TIMP-1 production. VSMC were stimulated for 24 h with either BK (10-8 M) or TGF-beta 1 (1 ng/ml), as positive control, in the presence and absence of anti-TGF-beta neutralizing antibody (20 µg/ml). The conditioned media were analyzed by Western blotting for TIMP-1 using specific anti-TIMP-1 antibody (1:2,000 dilution, Santa Cruz Biotechnology). The results shown in Fig. 4 demonstrate that both BK and TGF-beta 1 produced a significant increase in TIMP-1 production in VSMC (P < 0.05, control vs. BK or TGF-beta 1, n = 5). This increase in TIMP-1 production in response to either BK or TGF-beta 1 was completely blocked by the anti-TGF-beta neutralizing antibody, whereas the antibody alone had no effect on basal TIMP-1 production (Fig. 4).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   BK stimulates tissue inhibitor of metalloproteinase 1 (TIMP-1) secretion via autocrine activation of TGF-beta . VSMC were stimulated with 10-8 M BK or 1 ng/ml of TGF-beta 1 in presence or absence of 20 µg/ml of neutralizing anti-TGF-beta antibody (TGF-beta NA). Conditioned medium was collected after 24 h, and equal amounts of proteins were resolved on SDS-PAGE and immunoblotted with a polyclonal antibody against rat TIMP-1. Top: intensities of TIMP-1 bands expressed as percentage of control. Bottom: representative blot of 5 separate experiments. *P < 0.05 vs. control. dagger P < 0.02 vs. BK. #P < 0.05 vs. TGF-beta .

Activation of p42mapk and p44mapk by BK. MAPKs belong to the group of serine-threonine kinases that are rapidly activated in response to growth factors and appear to integrate multiple intracellular signals transmitted by various second messengers. To understand the signal transduction events mediated by BK, we examined its effects on MAPK activation. Treatment of VSMC with 10-8 M BK for 5 min resulted in a rapid increase in tyrosine phosphorylation of p42mapk and p44mapk, compared with unstimulated cells (Fig. 5). However, in the presence of the MAPK kinase inhibitor PD-98059 (40 µM), the increase in MAPK phosphorylation in response to BK was reduced. This finding is consistent with our previous observations demonstrating that BK activates MAPK in a concentration and time-dependent manner (28, 44).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Phosphorylation of p42mapk and p44mapk by BK in VSMC. VSMC were stimulated with BK (10-8 M) for 5 min in the presence and absence of MEK inhibitor PD-98059 (40 µM). Mitogen-activated protein kinase (MAPK) phosphorylations (p42mapk and p44mapk) were measured by immunoblot using anti-phosphotyrosine-MAPK antibodies (P-MAPK), and total MAPK was measured in the same immunoblot by stripping the membrane and immunoblotting with anti-total MAPK antibodies (T-MAPK). Bottom: blots are representative of 6 separate experiments. Top: intensities of both p42mapk and p44mapk bands measured in a densitometer relative to total MAPK and expressed as percent phosphorylation relative to control. *P < 0.01 vs. control. dagger P < 0.05 vs. BK.

Induction of TGF-beta 1 by BK is mediated via a MAPK-dependent pathway. To determine whether the increase in TGF-beta 1 mRNA in response to BK translates into an increase in TGF-beta 1 protein levels, TGF-beta 1 protein levels were measured in the conditioned media of VSMC stimulated with BK (10-8 M). As shown in Fig. 6, BK treatment resulted in a significant increase in TGF-beta 1 levels, compared with unstimulated control cells (84.5 ± 6.1 vs. 30.8 ± 2.9 pg/ml, BK vs. control, respectively, P < 0.0001, n = 5). To evaluate whether activation of MAPK modulates the BK-induced increase in TGF-beta 1 protein levels we observed, VSMC were treated with BK (10-8 M) in the presence of the MAPK inhibitor, PD-98059. The results shown in Fig. 6 demonstrate that inhibition of the MAPK pathway by PD-98059 completely eliminates the response of BK to stimulate TGF-beta 1 protein levels (84.5 ± 6.1 vs. 37.7 ± 2.7 pg/ml, BK vs. BK+PD-98059, P < 0.0001, n = 5).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6.   Induction of TGF-beta 1 protein secretion by BK in VSMC. Quiescent VSMC were stimulated with BK (10-8 M) for 48 h in presence or absence of MEK inhibitor PD-98059 (40 µM). Conditioned media were collected and activated to determine the total level of TGF-beta 1 protein, using a colorimetric ELISA kit assay. Values are means ± SE of TGF-beta 1 protein levels (expressed in pg/ml) and are representative of 5 separate experiments. *P < 0.0001 vs. control. #P < 0.0001 vs. BK.

Role of MAPK in BK-induced alpha 2(I) collagen and TIMP-1 expression. To examine whether activation of p42mapk and p44mapk modulates the increase in alpha 2(I) collagen promoter activity in response to BK, VSMC transfected with the alpha 2(I) collagen promoter were pretreated with the MAPK kinase inhibitor PD-98059 (40 µM) for 30 min, followed by BK (10-8 M) stimulation for 24 h. In the absence of PD-98059, BK produced a significant increase in CAT activity compared with unstimulated control cells (BK vs. control, P < 0.001, n = 5, Fig. 7A). This increase in CAT activity in response to BK stimulation was reduced significantly in the presence of MAPK kinase inhibitor (P < 0.04, BK vs. BK+PD-98059, Fig. 7A). The MAPK kinase inhibitor had no significant effect on basal CAT activity (Fig. 7A).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 7.   Role of MAPK in BK-induced alpha 2(I) collagen promoter activity and TIMP-1 production in VSMC. A: VSMC were transfected with a plasmid containing alpha 2(I) collagen promoter and CAT gene as a reporter for the activity of the alpha 2(I) collagen promoter. Transfected cells were stimulated for 24 h with 10-8 M BK in presence or absence of MEK inhibitor PD-98059 (40 µM). Bar graph represents the alpha 2(I) collagen promoter CAT activity expressed as percent of control and is representative of 5 experiments. B: VSMC were stimulated with 10-8 M BK in presence or absence of MEK inhibitor PD-98059 (40 µM). Conditioned media were collected and resolved on SDS-PAGE and immunoblotted with a polyclonal antibody against rat TIMP-1. Bar graph represents intensities of TIMP-1 bands expressed as percentage of control. Blot is representative of 4 separate experiments. *P < 0.05 vs. control. dagger P < 0.05 vs. BK.

To examine whether p42mapk and p44mapk also modulate the increase in TIMP-1 secretion in response to BK, VSMC were pretreated with the MAPK kinase inhibitor PD-98059 (40 µM) for 30 min, followed by BK (10-8 M) stimulation for 24 h. The release of TIMP-1 protein levels into the conditioned media was measured by Western blots using specific anti-TIMP-1 antibodies (1:2,000 dilution). BK produced a threefold increase in the secretion rate of TIMP-1 into the media compared with unstimulated cells (BK vs. C, P < 0.05, n = 4) (Fig. 7B). However, inhibition of MAPK activity significantly decreased TIMP-1 secretion in response to BK (BK vs. BK+PD-98059, P < 0.05, n = 4). The MAPK kinase inhibitor did not significantly alter basal secretion rate of TIMP-1.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The role of locally generated vasoactive factors in regulating vascular tone and structure under normal and pathological conditions has been increasingly emphasized. Among these factors, BK and angiotensin II are often considered to have opposite effects on vessel wall with regard to vascular reactivity and arterial compliance. Although the role of angiotensin II has been extensively studied with regard to vascular injury and remodeling, the precise role of BK on VSMC structure and the resultant fibrosis has not been well studied. In the present study we have demonstrated that BK induces the expression and transcriptional activation of alpha 2(I) collagen gene in VSMC. In addition, we have also shown that BK stimulates the production and secretion rate of TIMP-1. The increase in alpha 2(I) collagen mRNA levels, alpha 2(I) collagen promoter activity, and TIMP-1 production in response to BK are mediated via autocrine activation of TGF-beta 1. Moreover, the increase in alpha 2(I) collagen promoter activity, TGF-beta 1, and TIMP-1 production by BK involves activation of the MAPK pathway. These findings provide the first evidence that BK stimulates several key signaling pathways that participate in matrix dysregulation in VSMC.

Type I collagen represents up to two-thirds of total collagen, and total collagen constitutes about 60% of total atherosclerotic plaque protein composition (26, 37). Collagen type I is a heterotrimer consisting of two alpha 1(I) chains and one alpha 2(I) chain, which are expressed in a coordinated manner. The expression of type I collagen is strictly regulated through development and is tissue specific (31). In the present study, we have shown that BK stimulates the mRNA levels of alpha 2(I) collagen in VSMC. To begin to understand the mechanism of this collagen regulation by BK, we examined the effects of BK on VSMC transfected with the alpha 2(I) collagen promoter. Our results demonstrate that BK stimulates the alpha 2(I) collagen promoter activity, indicating that the increase in alpha 2(I) collagen mRNA levels in response to BK are mediated via transcriptional regulation. The alpha 2(I) collagen promoter is regulated by transcription factors such as SP1, SP3, CBF, and AP-1 (7, 41). We have previously shown that BK can induce the expression of protooncogene c-fos and c-jun, and the formation of AP-1 complex transcription factor (15). The increase in c-fos mRNA levels and the formation of AP-1 complex in response to BK were mediated via activation of p42mapk and p44mapk pathway (11, 28). In this regard, our data demonstrate that activation of p42mapk and p44mapk plays a critical role in mediating the effects of BK on collagen regulation. Thus inhibition of the MAPK pathway significantly reduced the increase in alpha 2(I) collagen promoter activity in response to BK. Therefore, one can speculate that activation of BK receptors in VSMC in response to BK results in activation of the MAPK pathway, which in turn results in the formation of the transcription factor AP-1, which leads to transcriptional activation of alpha 2(I) collagen gene.

TGF-beta is the most potent and consistent activator of collagen synthesis in VSMC (9). It increases the level of steady-state mRNA of alpha 2(I) and alpha 1(III) collagen in VSMC (1). In models of atherosclerosis such as rat balloon injury, TGF-beta was implicated as the factor responsible for the increase in collagen production. Transfection of TGF-beta gene into pig artery results in enhanced collagen type I production and accumulation (27). In the model of rat balloon injury, the injection of recombinant soluble TGF-beta type II receptor caused a marked reduction in mRNA levels for collagen type I and III, thus indicating the role of TGF-beta type II receptor in the fibrotic activity of TGF-beta (38). Similarly, in VSMC, a dominant-negative mutation of TGF-beta type II receptor abrogated the enhanced production of collagen type I induced by TGF-beta (46). However, the response of VSMC to TGF-beta can be different according to the cell origin (43). Hence, TGF-beta inhibits the cell growth and increases slightly the collagen synthesis in normal VSMC, whereas it stimulates cell growth and markedly induces collagen synthesis in VSMC isolated from atherosclerotic lesions (23). In the present study we have shown that TGF-beta plays a crucial role in mediating the effects of BK on matrix dysregulation. Our findings demonstrate that BK stimulates alpha 2(I) collagen mRNA levels and alpha 2(I) collagen promoter activity via autocrine activation of TGF-beta . Support for such a notion comes from the findings that addition of anti-TGF-beta neutralizing antibody reduces the mRNA levels and promoter activity of alpha 2(I) collagen in VSMC in response to BK. In addition, our findings demonstrate that BK induced the expression of TGF-beta 1 mRNA levels in VSMC as early as 4 h and also resulted in a marked increase in TGF-beta 1 protein levels. These findings provide the first evidence that BK stimulates collagen type I production in VSMC via autocrine induction of TGF-beta .

Matrix deposition can be viewed as the result of the balance between synthesis and degradation of ECM components. Matrix is degraded by MMPs, a family of neutral zinc proteases, which include the collagenases that degrade type I, III, and IV collagens, the gelatinases, and the stromelysins (10). The matrix proteases activity is blocked by a group of endogenous inhibitory proteins termed TIMP, which include TIMP-1, -2, -3, and -4 (13). Thus it is conceivable that the delicate balance between MMP and TIMP, as well as the rate of ECM synthesis, determines the final fate of matrix accumulation. TIMP-1 is a small glycoprotein synthesized by VSMC, which inhibits all the members of the MMP family and has been shown to participate in various physiological processes that involve tissue remodeling (13). The promoter of TIMP-1 contains multiple response elements in the 5' region of the gene, including an AP-1-binding site (20). No studies have addressed the effect of BK on TIMP-1 regulation in VSMC. Our study indicates that BK stimulates the production and secretion of TIMP-1 in VSMC and provides an additional pathway through which BK can influence ECM regulation. Since TGF-beta has been shown to stimulate the production of TIMP-1, we sought to determine whether BK stimulates TIMP-1 production via autocrine activation of TGF-beta . Addition of neutralizing antibody to TGF-beta completely eliminated the increase in TIMP-1 production in response to BK, thus implicating TGF-beta as a principal stimulator of TIMP-1 by BK in VSMC.

Although the cellular mechanisms through which BK mediates TIMP-1 production in VSMC are not defined, our results suggest a role for the MAPK pathway. Pretreatment of VSMC with the cell-permeable inhibitor of MAPK kinase significantly reduced the increase in TIMP-1 production in response to BK challenge, thus suggesting a role for p42mapk and p44mapk in modulating the production of TIMP-1 by BK. Another recent study has shown that the induction of TIMP-1 gene expression in fibroblasts in response to retinoic acid is also mediated via activation of p42mapk and p44mapk (3).

The role of MAPK in vascular dysfunction is just beginning to be emphasized. The p42mapk and p44mapk members of the MAPK family belong to a group of serine/threonine kinases that are rapidly activated in response to growth factor stimulation. They integrate multiple signals from various second messengers leading to cellular proliferation and differentiation (8, 40). The activated MAPK can translocate to the nucleus, where it is thought to regulate the expression of transcription factors such as c-fos through the phosphorylation of the transcription factor p62TCF and the formation of AP-1 binding site (12). Recently, it has been shown that MAPK activity is transiently activated following vessel wall injury, whereas MAPK phosphatase-1 is decreased (18, 19). In a model of myocardial infarction, MAPK activity was increased, along with the mRNA levels of TGF-beta and collagen types I and III (35). In addition, NIH 3T3 cells transfected with a dominant-negative mutant for MAPK kinase reduced the increase in collagen type I promoter activity in response TGF-beta (25). In the present study we have shown that BK mediates its fibrotic signals in VSMC via activation of the MAPK pathway. Inhibition of MAPK reduced the increase in alpha 2(I) collagen promoter activity, TGF-beta 1 protein levels, and production of TIMP-1 in response to BK. Other studies also support a role for MAPK in modulating the effects of TGF-beta on fibronectin production in VSMC (16).

In summary, our results suggest that BK initiate multiple signals that can result in fibrosis of VSMC. Our findings demonstrate that treatment of VSMC with BK results in an increase in alpha 2(I) collagen mRNA levels and promoter activity and an increase in the production of TIMP-1. The increase in alpha 2(I) collagen promoter activity and TIMP-1 production in response to BK are mediated via autocrine activation of TGF-beta and via activation of the MAPK pathway. The significance of these findings to the in vivo actions of BK and the vascular wall changes associated with injury or atherosclerosis is unclear at the present time. Further understanding of the cellular and molecular mechanisms by which BK might modulate vascular fibrosis, a process obligatory to the development of atherosclerosis, could lead to the development of new strategies for intervention and treatment of vascular diseases.


    ACKNOWLEDGEMENTS

This work was supported by National of Institutes of Health Grants HL-55782 and DK-46543, a Research Award from the American Diabetes Association (to A. A. Jaffa), a Merit Review Grant from the Research Service of the Department of Veterans Affairs (to R. K. Mayfield), a postdoctoral Award from the Juvenile Diabetes Foundation International (to V. Velarde), by National Heart, Lung, and Blood Institute Training Fellowship HL-07260 (to J. T. Christopher), and by a postdoctoral fellowship award from the Medical University of South Carolina (to C. D. Douillet).


    FOOTNOTES

Address for reprint requests and other correspondence: A. A. Jaffa, Dept. of Medicine, Endocrinology-Diabetes-Medical Genetics, Medical Univ. of South Carolina, 114 Doughty St., PO Box 250776, Charleston, SC 29425 (E-mail: jaffaa{at}musc.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 17 February 2000; accepted in final form 25 July 2000.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Amento, EP, Ehsani N, Palmer H, and Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 11: 1223-1230, 1991[Abstract/Free Full Text].

2.   Barnes, MJ. Collagens in atherosclerosis. Coll Relat Res 5: 65-97, 1985[ISI][Medline].

3.   Bigg, HF, McLeod R, Waters J, Cawston TE, Nolan JF, and Clark IM. Induction of human tissue inhibitor of metalloproteinase-1 gene expression by all-trans retinoic acid in combination with basic fibroblast growth factor involves both p42/44 and p38 MAP kinases. Ann NY Acad Sci 878: 506-509, 1999[ISI][Medline].

4.   Briner, VA, Tsai P, and Schrier RW. Bradykinin: potential for vascular constriction in the presence of endothelial injury. Am J Physiol Renal Fluid Electrolyte Physiol 264: F322-F327, 1993[Abstract/Free Full Text].

5.   Campbell, GR, Campbell JH, Ang AH, Campbell IL, Horrigan S, Manderson JA, Mosse PRL, and Rennick RA. Phenotypic changes in smooth muscle cells of human atherosclerotic plaques. In: Pathophysiology of the Atherosclerotic Plaque, edited by Glagove S, Newman WP, and Schaffer SA.. New York: Springer-Verlag, 1990, p. 69-93.

6.   Chirgwin, JJ, Przbyla AE, MacDonald RJ, and Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonucleases. Biochemistry 18: 5294-5299, 1979[Medline].

7.   Chung, KY, Agarwal A, Uitto J, and Mauviel A. An AP-1 binding sequence is essential for regulation of the human alpha 2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem 271: 3272-3278, 1996[Abstract/Free Full Text].

8.   Cobb, MH, and Goldsmith EJ. How MAP kinases are regulated. J Biol Chem 270: 14843-14846, 1995[Free Full Text].

9.   Davidson, JM, Zoia O, and Liu JM. Modulation of transforming growth factor-beta 1 stimulated elastin and collagen production and proliferation in porcine vascular smooth muscle cells and skin fibroblasts by basic fibroblast growth factor, transforming growth factor-alpha, and insulin-like growth factor-I. J Cell Physiol 155: 149-156, 1993[ISI][Medline].

10.   Dollery, CM, McEwan JR, and Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 77: 863-868, 1997[Free Full Text].

11.   El-Dahr, SS, Dipp S, and Baricos WH. Bradykinin stimulates the ERK-ELK-1-Fos/AP-1 pathway in mesangial cells. Am J Physiol Renal Physiol 275: F343-F352, 1998[Abstract/Free Full Text].

12.   Gille, H, Sharrocks AD, and Shaw PE. Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 358: 414-417, 1992[Medline].

13.   Gomez, DE, Alonso DF, Yoshiji H, and Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74: 111-122, 1997[ISI][Medline].

14.   Greene, EL, Velarde V, and Jaffa AA. Role of reactive oxygen species in bradykinin induced mitogen-activated protein kinase and c-fos induction in vascular cells. Hypertension 35: 942-947, 2000[Abstract/Free Full Text].

15.   Jaffa, AA, Ullian ME, Shankavaran U, Rosenzweig SA, and Mayfield RK. Bradykinin induces vascular smooth muscle cell proliferation (Abstract). Clin Res 42: 108, 1994.

16.   Kaiura, TL, Itoh H, and Kent KC. The role of mitogen-activated protein kinase and protein kinase C in fibronectin production in human vascular smooth muscle cells. J Surg Res 84: 212-217, 1999[ISI][Medline].

17.   Kichuk, MR, Seyedi N, Zhang X, Marboe CC, Michler RE, Addonizio LJ, Kaley G, Nasjletti A, and Hintze TH. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation. Circulation 94: 44-51, 1996[Abstract/Free Full Text].

18.   Lai, K, Wang H, Lee WS, Jain MK, and Haber E. Mitogen-activated protein kinase phosphatase 1 in rat arterial smooth muscle cell proliferation. J Clin Invest 98: 1560-1567, 1996[ISI][Medline].

19.   Lille, S, Daum G, Clowes MM, and Clowes AW. The regulation of p42/p44 mitogen-activated protein kinase in the injured rat carotid artery. J Surg Res 70: 178-186, 1997[ISI][Medline].

20.   Logan, SK, Garabedian MJ, Campbell CE, and Werb Z. Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors. J Biol Chem 271: 774-782, 1996[Abstract/Free Full Text].

21.   Majack, RA, and Clowes AW. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol 118: 253-256, 1984[ISI][Medline].

22.   Margolius, HS. Kallikrein and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 26: 221-229, 1995[Abstract/Free Full Text].

23.   McCaffrey, TA, Consigli S, Du B, Falcone DJ, Sanborn TA, Spokojny AM, and Bush HL. Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. J Clin Invest 96: 667-675, 1995.

24.   Mombouli, JV, and Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 35: 579-705, 1995.

25.   Mucsi, I, Skorecki KL, and Goldberg HJ. Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-beta1 on gene expression. J Biol Chem 271: 16567-16572, 1996[Abstract/Free Full Text].

26.   Murata, K, Motayama T, and Kotake C. Collagen types in various layers of the human aorta and their changes with the atherosclerotic process. Atherosclerosis 60: 251-262, 1986[ISI][Medline].

27.   Nabel, EG, Schum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, and Derynck R. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 90: 10759-10763, 1993[Abstract/Free Full Text].

28.   Naidu, PS, Velarde V, Kappler CS, Young RC, Mayfield RK, and Jaffa AA. Calcium-calmodulin mediates bradykinin-induced MAPK phosphorylation and c-fos induction in vascular cells. Am J Physiol Heart Circ Physiol 277: H1061-H1068, 1999[Abstract/Free Full Text].

29.   Nolly, H, Carretero OA, and Scicli AG. Kallikrein release by vascular tissue. Am J Physiol Heart Circ Physiol 265: H1209-H1214, 1993[Abstract/Free Full Text].

30.   Oza, N, Schwartz JH, Goud DH, and Levinsky NG. Rat aortic smooth muscle cells in culture express kallikrein, kininogen and bradykininase activity. J Clin Invest 85: 597-600, 1990.

31.   Ramirez, F, and Di Liberto M. Complex and diversified regulatory programs control the expression of vertebrate collagen genes. FASEB J 4: 1616-1623, 1990[Abstract].

32.   Rasmussen, LM, and Ledet T. Aortic collagen alternations in human diabetes mellitus. Changes in basement membrane collagen content and the susceptibility of total collagen to cyanogen bromide solubilization. Diabetologia 36: 445-453, 1993[ISI][Medline].

33.   Saed, G, Carretero OA, MacDonald RJ, and Scicli AG. Kallikrein messenger RNA in arteries and veins. Circ Res 67: 510-516, 1990[Abstract/Free Full Text].

34.   Scott-Burdent, T, Resnik TJ, Burgin M, and Buhler FR. Extracellular matrix: differential influence on growth and biosynthesis patterns of VSMC from SHR and WKY rats. J Cell Physiol 141: 267-274, 1989[ISI][Medline].

35.   Shimizu, N, Yoshiyama M, Omura T, Hanatani A, Kim S, Takeuchi K, Iwao H, and Yoshikawa J. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 38: 116-124, 1998[Abstract/Free Full Text].

36.   Siragy, HM, Jaffa AA, and Margolius HS. Bradykinin B2 receptors modulates renal prostaglandin E2 and nitric oxide. Hypertension 29: 757-762, 1997[Abstract/Free Full Text].

37.   Smith, EB. The influence of age and atherosclerosis on the chemistry of aortic intima. J Atheroscler Res 5: 241-248, 1965.

38.   Smith, JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, Koteliansky VE, and Lindner V. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 84: 1212-1222, 1999[Abstract/Free Full Text].

39.   Studer, RK, Negrete H, Craven PA, and DeRubertis FR. Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-beta bioactivity in mesangial cells. Kidney Int 48: 422-430, 1995[ISI][Medline].

40.   Su, B, and Karin M. Mitogen-activated protein kinases cascade and regulation of gene expression. Curr Opin Immunol 8: 402-411, 1996[ISI][Medline].

41.   Tamaki, T, Ohnishi K, Hartl C, LeRoy EC, and Trojanowska M. Characterization of a GC-rich region containing Sp1 binding site(s) as a constitutive responsive element of the alpha 2(I) collagen gene in human fibroblasts. J Biol Chem 270: 4299-4304, 1995[Abstract/Free Full Text].

42.   Thie, M, Harrach B, Schonherr E, Kresse H, Robenek H, and Rauterberg J. Responsiveness of aortic smooth muscle cells to soluble growth mediators is influenced by cell-matrix contact. Arterioscler Thromb 13: 994-1004, 1993[Abstract/Free Full Text].

43.   Thieszen, SL, Dalton M, Gadson PF, Patterson E, and Rosenquist TH. Embryonic lineage of vascular smooth muscle cells determines responses to collagen matrices and integrin receptor expression. Exp Cell Res 227: 135-145, 1996[ISI][Medline].

44.   Velarde, V, Ullian ME, Morinelli TA, Mayfield RK, and Jaffa AA. Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. Am J Physiol Cell Physiol 277: C253-C261, 1999[Abstract/Free Full Text].

45.   Wolf, G, Sharma K, Chen Y, Ericksen M, and Ziyadeh FN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta . Kidney Int 42: 647-656, 1992[ISI][Medline].

46.   Yamamoto, H, Ueno H, Ooshima A, and Takeshita A. Adenovirus-mediated transfer of a truncated transforming growth factor-beta (TGF-beta) type II receptor completely and specifically abolishes diverse signaling by TGF-beta in vascular wall cells in primary culture. J Biol Chem 271: 16253-16259, 1996[Abstract/Free Full Text].


Am J Physiol Heart Circ Physiol 279(6):H2829-H2837
0363-6135/00 $5.00 Copyright © 2000 the American Physiological Society



This article has been cited by other articles:


Home page
HypertensionHome page
J. Chao, H.-J. Li, Y.-Y. Yao, B. Shen, L. Gao, G. Bledsoe, and L. Chao
Kinin Infusion Prevents Renal Inflammation, Apoptosis, and Fibrosis via Inhibition of Oxidative Stress and Mitogen-Activated Protein Kinase Activity
Hypertension, March 1, 2007; 49(3): 490 - 497.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
N. S Hopkinson, K. I Eleftheriou, J. Payne, A. H Nickol, E. Hawe, J. Moxham, H. Montgomery, and M. I Polkey
+9/+9 Homozygosity of the bradykinin receptor gene polymorphism is associated with reduced fat-free mass in chronic obstructive pulmonary disease.
Am. J. Clinical Nutrition, April 1, 2006; 83(4): 912 - 917.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Sohn, Y. Tan, B. Wang, R. L. Klein, M. Trojanowska, and A. A. Jaffa
Mechanisms of low-density lipoprotein-induced expression of connective tissue growth factor in human aortic endothelial cells
Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1624 - H1634.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
A Del Rosso, O Distler, A F Milia, C Emanueli, L Ibba-Manneschi, S Guiducci, M L Conforti, S Generini, A Pignone, S Gay, et al.
Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement
Ann Rheum Dis, March 1, 2005; 64(3): 382 - 387.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
C. TSCHOPE, T. WALTHER, J. KONIGER, F. SPILLMANN, D. WESTERMANN, F. ESCHER, M. PAUSCHINGER, J. B. PESQUERO, M. BADER, H.-P. SCHULTHEISS, et al.
Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene
FASEB J, May 1, 2004; 18(7): 828 - 835.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Tan, F. N. Hutchison, and A. A. Jaffa
Mechanisms of angiotensin II-induced expression of B2 kinin receptors
Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H926 - H932.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. Cellier, M. Mage, J. Duchene, C. Pecher, R. Couture, J.-L. Bascands, and J.-P. Girolami
Bradykinin reduces growth factor-induced glomerular ERK1/2 phosphorylation
Am J Physiol Renal Physiol, February 1, 2003; 284(2): F282 - F292.
[Abstract] [Full Text] [PDF]